In a comprehensive presentation at the J.P. Morgan Healthcare Conference in San Francisco, Sandoz CEO Richard Saynor talked through many of Sandoz’s key strategic priorities, including its burgeoning biosimilars business, its consistent sales growth, and opportunities on the horizon in terms of upcoming losses of exclusivity – along with new product categories like GLP-1s and antibody drug conjugates (ADCs).
M&Ms And PBMs: Sandoz CEO Talks Antibiotics And Ustekinumab
Richard Saynor Discusses ‘Offensive’ US Antibiotics Pricing And Reveals Tie-Up For Stelara Rival
At the J.P. Morgan Healthcare Conference in San Francisco, Sandoz CEO Richard Saynor commented on the “offensively” low pricing for antibiotics in the US – “less than a packet of M&Ms” – while also revealing that the firm has struck a deal with a US PBM for its Samsung Bioepis-partnered Pyzchiva ustekinumab biosimilar to Stelara.
More from Strategy
• By
Teva is charting a new course under its ‘Pivot to Growth’ strategy, providing a memory aid for investors to better understand the firm’s financials going into 2025.
• By
Meitheal Pharmaceuticals said that its generic version of the GLP-1 agonist Victoza would be one of 22 planned launches during 2025, as the firm continues to build out its portfolio with the aid of its parent, Hong Kong King-Friend Industrial.
• By
Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.
Gedeon Richter has filed its Mochida-partnered tocilizumab biosimilar rival to RoActemra with the European Medicines Agency. But with several biosimilars already having won approval, the market could be competitive.
More from Generics Bulletin
• By
Off-patent drug trade groups expressed their concerns that personnel and expertise cuts will affect the agency’s ability to review and approve generics and biosimilars.
• By
Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.
• By
FDA staffing cuts are making negotiation preparations more difficult, but also could mean the result is a smaller user fee renewal package.